PortfoliosStock ScreensStocksStockXcel

Athira Pharma Inc

ATHA | US

1.41

USD

-0.04

-2.43%

ATHA | US

About Athira Pharma Inc

Sector

Healthcare

Industry

Biotechnology

Earnings date

30/09/2023

As of date

29/11/2023

Close

1.41

Open

1.45

High

1.49

Low

1.40

Athira Pharma Inc. a late clinical-stage biopharmaceutical company focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor MET for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020 an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105 an orally available brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents including dihexa the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma Inc. was formerly known as M3 Biotechnology Inc. and changed its name to Athira Pharma Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell Washington.

View Less

ATHA | US

Risk
87.1%
Sharpe
-0.98
Luna's Score
43/100
Recommendation
Sell

Luna says (ATHA | US)

What's Working

Low Debt to Equity (< 0.25)

Low Debt to Asset (< 0.2)

Value Stock (Price to Book < 3)

What's not Working

Negative Momentum (Declining Price)

Price Below SMA10D

High Short-term Volatility

Microcap (<300M USD)

No Dividends (Dividend Yield = 0%)

High Market Beta (> 0.8)

Weak Operating Margin (< 10%)

Weak Sharpe Ratio (< 0.3)

Volatility Signals

Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.

Risk Meter

10 days

73.4%

1 month

87.1%

3 months

65.0%

6 months

63.0%

Return

Fundamental Ratios

PE

0

Fwd. PE

0

Price to book

0.47

Debt to equity

0.01

Debt to assets

0.01

Ent. to EBITDA

1.15

Ent. to rev.

0

PEG

0

Other Fundamentals

EBITDA

-118.42M

MarketCap

53.47M

MarketCap(USD)

53.47M

Div. yield

0

Op. margin

0

Erngs. growth

0

Rev. growth

0

Ret. on equity

-57.80

Short ratio

3.86

Short perc.

1.91

Market Sentiment (SMA and Price signals)

Short-term: Bearish (SMA10D < SMA1M)

Intermediate-term: Bearish (SMA1M < SMA3M)

Long-term: Bearish (SMA6M < SMA12M)

SMAs: Stock Price Trends

Range10D

0.35

Range1M

0.44

Range3M

1.09

Volumes: Market Activity

Rel. volume

0.73

Price X volume

259.83K

Unlock Your Investing Potential

Register with Xstocks

Join over 2,000+ Investors

Register now and embark on your journey to informed and successful investing.

Explore Industry Correlations

Explore Industry Correlations

Uncover Trading and Hedging Opportunities

Gain valuable insights into potential trading opportunities and discover strategic hedging possibilities

Discover Top-Performing Industries

Discover Top performing Industries

Explore Stocks for Short and Long-Term Gains

Uncover opportunities at both short-term and long-term horizons, allowing you to make informed investment decisions.

Follow us @XStocks007